Search

Displaying results 5011 - 5020 of 10000 in total
  1. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  2. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    Like other amphetamines, this amphetamine analog was used as an appetite suppressant in the 1950s. … Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug.

  3. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs … that their blood can be regularly filtered using a dialysis machine.

  4. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. … The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus

  5. Drug

    Estazolam

    go.drugbank.com/drugs/DB01215
    ApprovedIllicitInvestigational

    A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.

    Synonyms: 8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
  6. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  7. Drug

    Norethynodrel

    go.drugbank.com/drugs/DB09371
    Approved

    As a contraceptive, it has usually been administered in combination with MESTRANOL. … A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis.

  8. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].

  9. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,

  10. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.